Enclomiphene
InvestigationalAlso known as: Androxal, trans-Clomiphene, Enclomiphene Citrate
Hormonal & ReproductiveLast reviewed: April 28, 2026
The trans-isomer of clomiphene citrate, a selective estrogen receptor modulator (SERM). Unlike the mixed isomer clomifene (Clomid), enclomiphene is the active anti-estrogenic component without the estrogenic zuclomiphene isomer. Studied as a treatment for secondary hypogonadism that preserves fertility, unlike exogenous testosterone.
Mechanism of Action
Blocks estrogen receptors in the hypothalamus, removing negative feedback on GnRH release. This increases pulsatile GnRH secretion, which stimulates pituitary LH and FSH production, driving endogenous testosterone synthesis while maintaining spermatogenesis.
Common Uses
- Secondary hypogonadism treatment
- Testosterone optimization without TRT
- Post-cycle therapy (PCT)
- Fertility preservation in hypogonadal men
- Alternative to clomiphene with fewer estrogenic side effects
Known Risks
- Headache
- Nausea
- Hot flashes
- Visual disturbances (less common than with clomiphene)
- Not FDA-approved — regulatory status uncertain
Regulatory Status
Not FDA-approved. Repros Therapeutics (now Allergan) submitted NDA for Androxal but received a Complete Response Letter in 2015. Currently available through compounding pharmacies. Active interest from telehealth clinics as a TRT alternative.
Common Protocols
Protocol information is for educational reference only. Dosing varies significantly by individual, condition, and physician guidance. Always work with a licensed healthcare provider.
Oral capsule
Typical Dose
12.5–25 mg
Frequency
Once daily
Cycle Length
Ongoing or 8–12 week cycles
Typically prescribed by telehealth clinics as a TRT alternative for men with secondary hypogonadism. Blood work (total T, free T, LH, FSH, estradiol) recommended at baseline and 6–8 weeks. Not the same as clomiphene (Clomid) — enclomiphene lacks the estrogenic zuclomiphene isomer.
Related Compounds
Research References
This information is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before starting any peptide therapy. Data is compiled from published research and regulatory sources and may not reflect the most recent developments.